Financial News Feed

Previous Hold Today AERI ranks #2099 as HOLD CANDIDATE. Next Hold
Today AERI ranks #2099 as HOLD CANDIDATE.

AERI stock Aerie Pharmaceuticals

AERI stock
Aerie Pharmaceuticals

Investors may be watching indicator signals on shares of Aerie Pharmaceutical (AERI). After a recent look, we have noted that the beta research opinion is currently Buy. This signal uses a system comb...

Read more

Investors are paying close attention to the charts of Aerie Pharmaceutical (AERI), as the shares are holding above the MACD Histogram zero line. The equity recently moved 0.00, touching 43.99 on a rec...

Read more

Sell-side analysts are offering a consensus “Buy” rating on shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and ...

Read more

The EBITDA Yield is a great way to determine a company’s profitability. This number is calculated by dividing a company’s earnings before interest, taxes, depreciation and amortization by the comp...

Read more

Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) has a current MF Rank of 16672. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are tra...

Read more

Mizuho restated their buy rating on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a report released on Friday. They currently have a $77.00 price target on the stock. “We are including weekly IQV...

Read more

Mizuho reaffirmed their buy rating on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a report released on Friday morning. The brokerage currently has a $77.00 price objective on the stock. “We are...

Read more

Tracking some short-term indicators on shares of Aerie Pharmaceutical (AERI) we note that the current 7-day average directional indicator is Buy. This signal can be used to determine the market trend....

Read more

In trying to determine the current valuation of Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) shares, we note that the Book to Market ratio of the shares stands at 0.137962. It’s commonly accepted tha...

Read more

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI), with a price target of ... The post Mizuho Securities Maintains a Buy Rating on Aerie Phar...

Read more

Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies....

Read more

Sentiment for Aerie Pharmaceuticals Inc (NASDAQ:AERI) Aerie Pharmaceuticals Inc (NASDAQ:AERI) institutional sentiment increased to 1.57 in Q3 2018. Its up 0.35, from 1.22 in 2018Q2. The ratio has incr...

Read more

Aerie Pharmaceuticals (NASDAQ:AERI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday. According to Zacks, “While the...

Read more

In trying to determine how profitable a company is per asset dollar, we can take a look at the firm’s Return on Assets. Return on assets is calculated by dividing a company’s net income (usually a...

Read more

Phase 2 Clinical Study Initiating Later in First Quarter 2019...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank